Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02220725 · ClinicalTrials.gov registry record · Phase 3
A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
A Phase 3 study of Bleeding, sponsored by Portola Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT02220725 is a Phase 3 study of Bleeding that has completed, run by Portola Pharmaceuticals. The registered enrollment target is 80 participants, below the 1,481-participant average among 23 other Bleeding trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02220725, a Phase 3 study of Bleeding, has completed, sponsored by Portola Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Rivaroxaban.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Andexanet
Study Locations (1)
California
- West Coast Clinical Trials - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02220725
The ClinicalTrials.gov registry entry for NCT02220725 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,481-participant average among 23 other Bleeding trials with a reported enrollment target (95% lower). The listed sponsor is Portola Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bleeding appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02220725 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02220725 about?
NCT02220725 is a clinical study titled "A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban". The purpose of this study is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Rivaroxaban.
What is the current status of trial NCT02220725?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2014-05. Estimated completion is 2015-08.
What conditions does trial NCT02220725 study?
This clinical trial studies the following conditions: Bleeding.
What interventions are being tested in trial NCT02220725?
The interventions under investigation include: Placebo (OTHER), Andexanet (BIOLOGICAL).
Who is sponsoring clinical trial NCT02220725?
This trial is sponsored by Portola Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02220725 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
-
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
RECRUITING · Phase 2
-
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
RECRUITING
-
Quantra Point-of-Care Hemostasis Monitoring
RECRUITING · NA
-
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device
RECRUITING · Phase 4
-
Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.